Myriad Genetics reported Q4 FY2025 revenue of USD 209.8 million (flat year-over-year), with test volumes of 382,000 (+2% year-over-year) and gross margin of 70.0%. Q4 GAAP net loss was USD 7.9 million, or USD 0.08 per share, while adjusted EPS was USD 0.04 and adjusted EBITDA was USD 14.3 million. Operating expenses were USD 152.5 million (-USD 37.4 million year-over-year) and operating loss was USD 5.7 million. Cash flow provided by operations was USD 10.6 million and cash and cash equivalents ended the quarter at USD 149.6 million. For FY2025, Myriad posted revenue of USD 824.5 million (-2% year-over-year) and test volumes of 1.54 million (+1% year-over-year). By product category in Q4, hereditary cancer revenue was USD 96.8 million (+3%), tumor profiling revenue was USD 31.5 million (+2%), prenatal revenue was USD 44.9 million (flat), and mental health (GeneSight) revenue was USD 36.6 million (-10%), with the company citing UnitedHealthcare’s discontinuation of coverage for multi-gene panel pharmacogenetic testing, including GeneSight, effective in Q1 FY2025. Business updates included plans for three test launches in 2026: a targeted alpha launch of Precise MRD for breast cancer expected in March 2026, a full commercial launch of an AI-enabled Prolaris prostate cancer test with PATHOMIQ expected in Q2 2026, and a multiple prenatal screen test, FirstGene, expected in H2 2026. Myriad also highlighted an integrated AI and genetic breast cancer risk platform launched with Clairity and MagView, and reported positive interim outcomes from the MONSTAR-SCREEN-3 colorectal cancer study incorporating Precise MRD, including 100% baseline sensitivity. The company reiterated FY2026 guidance for revenue of USD 860 million to USD 880 million and adjusted EBITDA of USD 37 million to USD 49 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9659444-en) on February 23, 2026, and is solely responsible for the information contained therein.